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Abstract
Introduction—Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical 
syndrome in need of improved phenotypic classification. We sought to evaluate whether unbiased 
clustering analysis using dense phenotypic data (“phenomapping”) could identify phenotypically 
distinct HFpEF categories.
Methods and Results—We prospectively studied 397 HFpEF patients and performed detailed 
clinical, laboratory, electrocardiographic, and echocardiographic phenotyping of the study 
participants. We used several statistical learning algorithms, including unbiased hierarchical 
cluster analysis of phenotypic data (67 continuous variables) and penalized model-based clustering 
to define and characterize mutually exclusive groups comprising a novel classification of HFpEF. 
All phenomapping analyses were performed blinded to clinical outcomes, and Cox regression was 
used to demonstrate the clinical validity of phenomapping. The mean age was 65±12 years, 62% 
were female, 39% were African-American, and comorbidities were common. Although all patients 
met published criteria for the diagnosis of HFpEF, phenomapping analysis classified study 
participants into 3 distinct groups that differed markedly in clinical characteristics, cardiac 
structure/function, invasive hemodynamics, and outcomes (e.g., pheno-group #3 had an increased 
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risk of HF hospitalization [hazard ratio 4.2, 95% CI 2.0–9.1] even after adjustment for traditional 
risk factors [P<0.001]). The HFpEF pheno-group classification, including its ability to stratify 
risk, was successfully replicated in a prospective validation cohort (n=107).
Conclusions—Phenomapping results in novel classification of HFpEF. Statistical learning 
algorithms, applied to dense phenotypic data, may allow for improved classification of 
heterogeneous clinical syndromes, with the ultimate goal of defining therapeutically homogeneous 
patient subclasses.
Keywords
diastolic heart failure; cluster analysis; principal components analysis; echocardiography; 
outcomes
INTRODUCTION
Heart failure (HF), regardless of underlying ejection fraction (EF), is a heterogeneous 
syndrome, the end result of one or more risk factors that ultimately lead to abnormal cardiac 
structure and function, which in turn causes reduced cardiac output and/or elevated cardiac 
filling pressures at rest or with exertion.1 Despite its underlying heterogeneity, HF with 
reduced ejection fraction (HFrEF), particularly outpatient HFrEF, has proven to respond to a 
“one size fits all” approach, with several drugs and devices shown to improve outcomes in 
randomized clinical trials. Unlike in HFrEF, clinical trials of pharmacologic agents in HF 
with preserved ejection fraction (HFpEF) have been universally disappointing, and no 
treatments have improved outcomes in this group of patients.2 In HFpEF, the underlying 
phenotypic heterogeneity is likely far greater than in HFrEF,3, 4 and may be a key reason for 
the poor track record of HFpEF clinical trials. Therefore, understanding the phenotypic 
heterogeneity of HFpEF, which includes the etiologic and pathophysiologic heterogeneity of 
the syndrome, may allow for more targeted (and more successful) HFpEF clinical trials. An 
ideal HFpEF classification system would group together pathophysiologically similar 
individuals who may respond in a more homogeneous, predictable way to treatment.
The problem of unresolved heterogeneity is not unique to medicine—and in fact appears 
routinely in such fields as document classification and image processing.5 Machine learning
—the process of using data to learn relationships between objects—is ideally suited for this 
task.6 Machine learning approaches are typically subdivided into 2 categories: supervised 
and unsupervised. Supervised learning seeks to predict specified outputs or outcomes. The 
goal of unsupervised learning, on the other hand, is to try to learn the intrinsic structure 
within data—such as the analysis of genomic data to derive new subclasses of tumors. 
Although seemingly distinct, there is considerable overlap between these two categories of 
learning; unsupervised learning is increasingly seen as an invaluable initial strategy to derive 
robust set of features for novel classification of a disease or clinical syndrome, which can 
subsequently be used for supervised learning in a variety of settings.5, 7, 8
With the advent of sophisticated phenotyping tools ranging from a multitude of biomarkers 
to comprehensive cardiovascular imaging modalities, the era of “deep phenotyping” is now 
available to improve characterization of heterogeneous syndromes like HFpEF. Prior studies 
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in disease areas such as cancer and autoimmune disease have successfully coupled genomic 
characterization or protein expression with machine learning approaches,7–9 although such 
strategies have typically relied on molecular profiling of the tissue of interest. Within the 
field of cardiovascular medicine, prior studies have utilized supervised learning algorithms 
such as neural networks and decision tree analysis as methods for assisting with diagnosis 
and clinical decision-making, respectively;10, 11 however, no prior study has used these 
techniques to better classify heterogeneous cardiovascular syndromes such as HFpEF. We 
hypothesized that applying statistical/machine learning algorithms to dense phenotyping 
alone would allow for the detection of novel patterns in dense, multi-dimensional data 
obtained from HFpEF patients. We further hypothesized that the identified “pheno-groups” 
of HFpEF patients would have unique pathophysiologic profiles and differential outcomes. 
We therefore prospectively investigated the utility of unbiased phenotype mapping (i.e., 
“phenomapping”) algorithms in a well-characterized HFpEF cohort.
METHODS
Study population
Between March 2008 and May 2011, 420 consecutive patients were prospectively enrolled 
from the outpatient clinic of the Northwestern University HFpEF Program as part of a 
systematic observational study of HFpEF (ClinicalTrials.gov identifier #NCT01030991). All 
patients were recruited after hospitalization for HF. Patients were initially identified by an 
automated daily query of the inpatient electronic medical record at Northwestern Memorial 
Hospital using the search criteria: (1) diagnosis of HF or the words “heart failure” in the 
hospital notes; or (2) B-type natriuretic peptide (BNP) >100 pg/ml; or (3) administration of 
2 or more doses of intravenous diuretics. The list of patients generated was screened daily, 
and only those patients with an LV ejection fraction (LVEF) > 50% and who met 
Framingham criteria for HF12 were offered post-discharge follow-up in a specialized HFpEF 
outpatient program. The HF diagnosis was confirmed in the post-hospitalization outpatient 
HFpEF clinic. Based on previously published criteria,13 besides the presence of 
symptomatic HF and LVEF > 50%, we required evidence of either significant diastolic 
dysfunction (grade 2 or 3) on echocardiography or evidence of elevated LV filling pressures 
on invasive hemodynamic testing or BNP > 100 pg/ml. Patients with greater than moderate 
valvular disease, prior cardiac transplantation, prior history of reduced LVEF < 40% (i.e., 
“recovered” EF), or diagnosis of constrictive pericarditis were excluded. All study 
participants gave written, informed consent, and the institutional review board at 
Northwestern University approved the study. Descriptions of the clinical characteristics 
collected on the study participants, definitions of comorbidities, and echocardiography, non-
invasive pressure-volume analysis, and invasive hemodynamics methods are provided in the 
Supplementary Data section.
Phenotypic domains
Table 1 demonstrates the phenotype domains and individual continuous variables that served 
as phenotypic features for the phenomapping analysis. The phenotypic domains included 
clinical variables, physical characteristics, laboratory data, electrocardiographic parameters, 
and echocardiographic parameters.
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After enrollment, all study participants were evaluated in the Northwestern HFpEF Program 
as clinically indicated but at least every 6 months. At each visit, inter-current 
hospitalizations were documented, reviewed, and categorized as due to cardiovascular or 
non-cardiovascular causes. For cardiovascular hospitalizations, specific causes (e.g., HF, 
acute coronary syndrome, arrhythmia) were identified. Every 6 months, participants (or their 
proxy) were contacted to determine vital status with verification of deaths through query of 
the Social Security Death Index. Enrollment date was defined as the first visit to the 
outpatient HFpEF clinic. Date of last follow-up was defined as date of death or last HFpEF 
clinic visit. Follow-up was complete in all patients.
Exploration of the relationship between phenotypic variables
Prior to analysis, missing data (see Supplementary Figure S1) was imputed using the 
SVDimpute function within the impute package in R. Briefly, missing values were imputed 
using regression with eigenvectors as predictors. An iterative process was taken where all 
missing values are set to the row mean, eigenvectors are computed for the data matrix (using 
SVD) and a given number (5) of eigenvectors were used to impute missing values. The 
percentage of missing values for features ranged from 0% to 24% (for estimated pulmonary 
arterial systolic pressure). Hierarchical clustering was used to visualize redundancy among a 
total of 67 continuous phenotypic variables (Table 1). First, a correlation matrix of 
phenotypic variables was generated based on the absolute value of the Pearson correlation 
coefficient. Correlation profiles were used to eliminate redundant features. Variables that 
were correlated at a correlation coefficient of > 0.6 were filtered (keeping the variable that 
was most informative and had the least missingness), leaving 46 continuous variables for the 
final phenomapping analyses.
Biclustering of HFpEF subjects and phenotypic variables
Agglomerative hierarchical clustering, a commonly used unsupervised learning tool, was 
adapted for the purpose of grouping patients and phenotypic variables.6 The 46 continuous 
phenotypic variables identified after filtering were standardized to mean=0 and standard 
deviation=1. Hierarchical clustering was performed using the hclust function in R (3.0.1), 
with the dissimilarity matrix given by Euclidean distance and the average linkage score used 
to join similar clusters. Subsequent optimal leaf reordering was performed using the 
seriation package in R14 so that within a given branch, more similar rows/columns were 
grouped together. A visual representation of the resulting heatmap was generated using the 
hmap function. All clustering was performed blinded to clinical outcome data.
Penalized model-based clustering of participants
Although hierarchical clustering is effective as a means of visualization, it is problematic to 
use as a method for grouping patients into discrete clusters given the heuristic nature of the 
algorithm and the arbitrariness of defining height thresholds on the resulting dendrogram. To 
determine the optimal number of pheno-groups within the HFpEF cohort, we therefore used 
model-based clustering, which assumes a Gaussian distribution for values of phenotypic 
variables within a cluster, and achieves parameter fitting and patient assignment by 
Shah et al. Page 4













minimizing a penalized likelihood.15 Specifically we used the mclust package in R and 
explored a full range of covariance structures, some of which relax the requirement for 
independence of features (i.e. non-diagonal covariance matrices). The Bayesian information 
criterion (BIC) was used to penalize increases in model complexity, such as a greater 
number of clusters or variability in standard deviation across variables and across clusters. 
As a result a parsimonious solution is reached. Such penalty functions serve as a means of 
“regularization” in machine learning, and improve generalizability to other data sets.6 In our 
implementation, we tried between 1 and 8 clusters.
Comparison of clinical characteristics and survival among pheno-groups
Once phenotype groups were defined, we compared differences in demographic, clinical, 
electrocardiographic, echocardiographic, and invasive hemodynamic characteristics among 
groups using Chi-squared tests (or Fisher exact tests when appropriate) for categorical 
variables and analysis of variance (or Kruskal-Wallis test, when appropriate) for continuous 
variables. For outcomes analyses, we used unadjusted and multivariable adjusted Cox 
proportional hazards models to determine the independent association between phenotype 
groups and outcomes. The proportionality assumption was tested and verified for all Cox 
regression models. We defined the primary outcome as cardiovascular hospitalization or 
death, and the secondary outcome as heart failure hospitalization. Covariates included in the 
multivariable model included variables known to be predictive of outcomes in HFpEF. We 
used the likelihood ratio test to determine whether the phenotype group variable was 
predictive of outcomes beyond BNP and the MAGGIC risk score16 (a recently developed 
mortality risk score for patients with HF, including HFpEF). Finally, we used receiver-
operating characteristic (ROC), net reclassification improvement (NRI), and integrated 
discrimination improvement (IDI) analyses to determine the prognostic and discriminative 
utility of the pheno-group variable.
Statistical analyses for comparison of clinical data among groups, and for the association of 
phenotype groups with outcomes, were performed using Stata v.12 (StataCorp, College 
Station, TX).
Validation cohort
We performed an independent validation analysis in 107 additional HFpEF patients who 
were prospectively enrolled and followed for outcomes in the Northwestern HFpEF Program 
between January 2012 and February 2014. These additional study participants were 
identified in the same manner, and met the same inclusion and exclusion criteria, as the first 
420 HFpEF study participants. Phenotypic data from the validation cohort was normalized 
entirely independently (thus avoiding any contamination from the training data [i.e., original 
cohort]), and patients were assigned to the original phenogroups using the predict function 
within mclust. We then looked to see whether there was again a difference in outcomes 
among the 3 groups, using the same outcomes analyses (Cox regression) as those used in the 
original cohort.
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Supervised learning analyses for the prediction of disease outcomes
The unsupervised statistical learning analyses outlined above assume that there are naturally 
occurring subclasses within HFpEF that behave differently yet reproducibly across a number 
of populations and across varying scenarios (e.g. varying treatments, environments, etc.). 
Thus, the first part of our study emphasizes finding intrinsic structure within HFpEF patient 
phenotypic data, which can then be evaluated retrospectively and prospectively for 
predicting treatment outcomes and guiding clinical trial design.
One can also use the same set of phenotypic features simply to predict clinical outcome, 
without emphasizing any natural structure in the data (i.e., supervised learning analyses). 
We explored the use of support vector machines (SVM), a machine algorithm that identifies 
a separation boundary between classes of interest in a much higher dimensional feature 
space. SVM is a robust non-linear algorithm that can be used for classification or 
regression.17 We coded each of the cardiovascular outcomes (HF hospitalization, 
cardiovascular hospitalization, death, and the combined outcome of cardiovascular 
hospitalization or death) as binary outcomes (i.e., ignoring right-censoring), and used SVM 
with the 46 phenotypic predictors to predict outcome. We evaluated radial and sigmoid basis 
functions, tuning the values of the gamma and cost parameters using the derivation cohort, 
and evaluating performance on the validation cohort. Performance was evaluated using area 
under the receiver operating characteristic curve (AUROC), as well as mean sensitivity, 
mean specificity, and mean precision.
RESULTS
Characteristics of the HFpEF cohort
We prospectively enrolled 420 patients with HFpEF for our initial phenomapping analysis. 
Of the 420 patients, 23 had incomplete phenotypic data, including incomplete 
echocardiographic data. Thus, the final cohort consisted of 397 HFpEF patients. All enrolled 
patients were previously hospitalized for HF (though all patients were enrolled and studied 
in the outpatient HFpEF clinic). Similar to previous studies of HFpEF, patients were 
symptomatic based on NYHA functional class and had multiple comorbidities (Tables 2 and 
3).18, 19 Several features corroborated the diagnosis of HFpEF in the study cohort: preserved 
LVEF, normal LV end-diastolic volume index, increased LA volume index, increased LV 
filling pressures (E/e′ ratio), a high frequency of moderate or greater diastolic dysfunction, 
and elevated BNP (Table 2).13 In the 216 patients who underwent invasive hemodynamic 
testing, mean pulmonary capillary wedge pressure was 23±9 mmHg at rest, confirming the 
presence of elevated LV filling pressures.
Exploration of the continuous phenotypic variables
We first examined the phenotypes to determine the correlation among them and found that 
although some variables were correlated with each other, there were not tight correlations 
across large numbers of phenotypes. Nevertheless, as stated above, phenotypes that were 
correlated at r > 0.6 were filtered, leaving 46 minimally redundant phenotypes. These 
features were used for subsequent unsupervised and supervised learning analyses.
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All study participants met common diagnostic criteria for HFpEF. Nonetheless, the 
phenotype heatmap created for HFpEF by hierarchical clustering (Figure 1) demonstrated 
substantial heterogeneity among study subjects. Within the heatmap, clusters of individuals 
with shared characteristics (“hotspots”) can be highlighted, corresponding in part to elevated 
activity of various pathophysiologic features such as increased right heart pressures and RV 
wall thickness, cardiac chamber enlargement, and elevated body size. However, these traits 
seemed to co-occur in varying patterns. For example, RV dilation seemed to occur in some 
individuals with poor renal function, in another subset with elevated right heart pressures, 
and in a third group with neither of the above. Unanticipated correlations between traits 
were also seen, such as between red cell distribution width and left atrial volume.
A parsimonious classification of HFpEF
After examining the relationship between phenotypic features, our next goal was to group 
patients into a minimal group of clusters that accurately reflected the phenotypic variability. 
A variety of unsupervised learning methods can be used for this task. We elected to use 
model-based clustering, a method that attempts to define clusters of individuals by 
multivariate normal distributions of phenotypic variables.15 An important feature of this 
implementation of model-based clustering is the use of a penalty function to control the 
amount of complexity in the model – thus allowing a parsimonious description of the 
patients in the data set. Our analysis arrived at 3 as the optimal number of clusters (Figure 
2), and allowed for some flexibility in the “shapes” of the multivariate normal distribution 
across clusters.
Comparison of clinical characteristics and laboratory, electrocardiographic, 
echocardiographic, and invasive hemodynamic data among pheno-groups
The 3 pheno-groups were significantly different from each other. As shown in Table 3, 
pheno-group #1 was younger and had lower BNP than participants in the other groups. 
Pheno-group #2 had the highest prevalence of obesity, diabetes, and obstructive sleep apnea 
and had the highest fasting glucose. Pheno-group #3 was the oldest, more likely to have 
chronic kidney disease (with the highest serum creatinine and lowest GFR), and had the 
highest BNP and MAGGIC risk score values. Table 4 displays the large variation in 
electrocardiographic characteristics, cardiac structure and function, and invasive 
hemodynamic data across the pheno-groups. Pheno-group #1 had the least electrical and 
myocardial remodeling and dysfunction, and the least hemodynamic derangement, although 
it should be noted that even within this group, 65% had at least grade 2 (moderate) diastolic 
dysfunction, mean PCWP was 20 mmHg, and the average invasive pulmonary artery 
systolic pressure was 42 mmHg. Pheno-group #2 had the worst LV relaxation (i.e., lowest e′ 
velocity), highest pulmonary capillary wedge pressure, and highest pulmonary vascular 
resistance. Finally, pheno-group #3 had the most severe electrical and myocardial 
remodeling with the longest QRS duration, largest QRS-T angle, highest relative wall 
thickness and LV mass index, highest E/e′ ratio, and worst RV function. Despite these 
differences between pheno-groups, HF duration was similar among the 3 groups (Table 3). 
On LV pressure-volume analysis, all 3 pheno-groups had similar end-systolic and end-
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diastolic elastances (Supplementary Table S1). However, in terms of stroke work and related 
phenotypes, pheno-groups #1 and #2 were similar, while pheno-group #3 was worst. 
Ventricular-arterial coupling was also most abnormal, and pulse pressure/stroke volume 
ratio highest, in pheno-group #3. In addition, despite similar end-systolic and end-diastolic 
elastance values among the 3 groups, RV remodeling and dysfunction were more prominent 
in pheno-group #3 (as shown in Table 4).
Association of pheno-groups with adverse outcomes
In order to provide external clinical validity of our phenomapping techniques, we studied the 
relationship between the pheno-groups and adverse outcomes. As shown in Table 5 and 
Figures 3 and 4, outcomes varied significantly by pheno-group, with a step-wise increase in 
risk profile going from lowest risk (pheno-group #1) to highest risk (pheno-group #3). 
Pheno-group #3 in particular represented a high-risk subset, independent of BNP (known to 
be one of the most potent risk markers in HF) and the MAGGIC HF risk score, which 
comprises 13 traditional clinical parameters. Table 6 shows that the phenomapping 
technique created pheno-groups with differential risk profiles that provided better 
discrimination compared to clinical parameters (i.e., the MAGGIC risk score) and BNP. 
Based on the IDI, NRI, and likelihood ratio tests, the pheno-group assignment provided 
prognostic information above and beyond traditional clinical variables. In addition, the 
association between pheno-group membership and outcomes persisted after adjustment for 
HF duration.
Validation of the phenomapping analyses
In order to validate our phenomapping results, we prospectively enrolled an additional 107 
patients in the HFpEF program. For the most part, these 107 new HFpEF participants had 
clinical, laboratory, and echocardiographic characteristics that were similar to the original 
HFpEF cohort (Supplementary Tables S2 and S3). There were less African Americans, less 
chronic obstructive pulmonary disease, less thiazide diuretic use, and worse RV fractional 
area change in the validation cohort; however, there were no differences in age, sex, NYHA 
functional class, LVEF, LV mass index, diastolic function grade, or E/e′ ratio between the 
original and validation cohorts. Using model-based clustering, each of the HFpEF validation 
cohort participants was successfully matched to 1 of the 3 previously defined pheno-groups 
(37/107 [34.6%] in pheno-group #1; 29/107 [27.1%] in pheno-group #2; and 41/107 [38.3%] 
in pheno-group #3).
Pheno-group membership in the validation cohort was independently associated with 
adverse outcomes, with a step-wise increase in risk profile going from lowest risk pheno-
group (#1) to highest risk pheno-group (#3) (Supplementary Table S4). Pheno-group #3 in 
the validation cohort, as in the original cohort, was associated with adverse outcomes 
independent of BNP and the MAGGIC HF risk score with hazard ratios comparable to the 
training cohort (for the combined end-point of cardiovascular hospitalization, HF 
hospitalization, or death: unadjusted HR 3.6, 95% CI 1.6–8.4, P=0.003); adjusted HR 3.3, 
95% CI 1.1–9.5, P=0.026).
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After tuning SVM analyses to build optimal models for predicting a combined outcome of 
death and cardiovascular hospitalization (which includes HF hospitalization), and also for 
individual outcomes, we found that model performance was typically good, with AUROC 
values ranging from 0.70–0.76 in the validation cohort (Supplementary Table S5).
DISCUSSION
In a cohort of 397 patients with documented HFpEF, along with a validation cohort of 107 
independent HFpEF patients, we have shown the feasibility and clinical validity of a novel 
classification technique for HFpEF, a heterogeneous clinical syndrome. Taking techniques 
commonly used for the analysis of gene expression data,20 and applying these to dense 
phenotypic data, we were able to show the following: (1) HFpEF truly is a heterogeneous 
disorder; (2) despite the heterogeneity of HFpEF, phenomapping analysis of HFpEF patients 
produces mutually exclusive groups of individuals with related comorbidities and 
pathophysiologies; and (3) the identified pheno-groups have differential outcomes indicating 
differing risk profiles and clinical trajectories. To our knowledge, our study provides the 
first description of phenomapping for the novel classification of a cardiovascular disorder, 
and it is the first study that applies machine learning techniques to resolve heterogeneity in a 
cardiovascular syndrome using dense phenotypic data.
Using a variety of algorithms, we were able to take advantage of the deep phenotyping in 
our HFpEF cohort and find unique patterns of association among phenotypic variables, 
which allowed for a novel, unique grouping of study participants. Although all patients met 
established criteria for HFpEF, the PhenoMap (Figure 1) clearly demonstrates that HFpEF is 
a heterogeneous syndrome. Modern visualization methods provide a complete and striking 
depiction of the high variability of HFpEF that is clinically apparent when caring for these 
patients.
The robust assignment of group membership (i.e., clustering of HFpEF patients into 
categories) was possible due to our use of penalized machine learning techniques such as 
model-based clustering, which in turn are based on the solid foundation of parametric 
estimates of clustering individuals and regularization via the Bayesian information criterion 
(as shown in Figure 2). Thus, it appears that given this diverse collection of phenotypic 
variables, 3 mutually exclusive pheno-groups represents an optimal number for HFpEF.
Once the 3 pheno-groups were identified, the differences among them (as shown in Tables 3 
and 4) were striking. Study participants within the 3 pheno-groups, despite having shared 
diagnostic features of HFpEF, differed markedly on almost every characteristic. From these 
analyses it became clear that the 3 pheno-groups represent 3 archetypes of HFpEF: (1) 
younger patients with moderate diastolic dysfunction who have relatively normal BNP; (2) 
obese, diabetic patients with a high prevalence of obstructive sleep apnea who have the 
worst LV relaxation; and (3) older patients with significant chronic kidney disease, electrical 
and myocardial remodeling, pulmonary hypertension, and RV dysfunction.
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As an independent measure of the distinctness of our classification, we undertook clinical 
validation through the association of pheno-groups with adverse outcomes, which showed 
the robust ability of pheno-group membership (derived from unsupervised statistical 
learning analyses) as a method for risk stratification in HFpEF participants. In addition, we 
show that supervised learning analyses such as SVM can be applied to a rich dataset of 
quantitative phenotypic data for risk stratification in HFpEF. However, it is essential to note 
that while we were able to show that pheno-group membership was an important, 
independent predictor of differential outcomes, the aim of our study was not to create a new 
method for risk stratification. HFpEF risk prediction techniques, such as the MAGGIC risk 
score,16 are already available. Instead, the primary goal of our study was to show that using 
an unbiased approach allows for the clustering of patients into distinct, mutually exclusive 
groups that could be used to target specific therapies in the clinic and in clinical trials. It is 
for these same reasons that we chose to employ unsupervised machine learning algorithms 
(instead of supervised learning algorithms). Although methods such as neural networks and 
support vector machines,6 can be tremendously powerful for risk stratification, our emphasis 
was on highlighting distinct prototypes of HFpEF, which may be driven by fundamentally 
different underlying pathophysiologic mechanisms and thus have distinct responses in 
clinical trials. Moreover, the growing success of “deep learning” algorithms21 has 
demonstrated that pre-training with unsupervised learning approaches, as we have done, can 
be an effective means of higher order feature extraction and can markedly improve the 
performance of subsequent supervised approaches.5
Our study has several important ramifications for the study of HFpEF and the design of 
future HFpEF clinical trials. While epidemiologic studies and observational registries of 
HFpEF have enrolled a wide variety of patients with varying etiology and pathophysiology, 
detailed mechanistic studies of HFpEF often only enroll very specific subsets of patients 
with a “pure phenotype”, therefore limiting their generalizability to the larger population of 
HFpEF patients. For example, in a pathophysiologic study of HFpEF,22 Prasad and 
colleagues began with 1119 patients hospitalized for HF with EF > 50%. After applying 
their exclusion criteria, which included common HFpEF comorbidities such as atrial 
fibrillation, chronic kidney disease, myocardial infarction, and cognitive impairment, only 
23 (2%) of patients remained eligible for their study.22 Thus, the pathophysiologic studies 
that have concluded that HFpEF is mainly a disease of diastolic dysfunction have been 
challenged,23 and several studies have now shown that HFpEF is quite heterogeneous from 
both an etiologic and pathophysiologic standpoint.4, 24–26 Our study confirms the 
heterogeneity of HFpEF in an unselected group of high-risk, previously hospitalized HFpEF 
patients.
With the advent of sophisticated phenotyping tools ranging from a multitude of biomarkers 
to comprehensive cardiovascular imaging modalities to environmental characterization and 
activity monitoring, the era of “deep phenotyping” is now available to improve 
characterization of heterogeneous syndromes like HFpEF. Here we have shown that 
combined with machine learning algorithms to find patterns in dense, multi-dimensional 
data, novel phenotypic characterization of HFpEF is possible. Future clinical trials can 
harness these advances in phenotypic categorization by deep phenotyping of study 
participants using banked blood and cardiac imaging (such as comprehensive 
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echocardiography), along with other tools (e.g., quality of life measures, exercise tests, etc.) 
as needed, which will allow for the development of phenotype heatmaps. These analyses can 
then be used in the clinical trial setting to determine whether certain groups of patients are 
more responsive to the investigational drug or device compared to other types of patients, 
thereby leading to improved future clinical trials and/or “theranostics”, a combined 
diagnostic and therapeutic treatment strategy.
Strengths and Limitations
Our study has several strengths, including the inclusion of a large, well-phenotyped HFpEF 
cohort; unselected, high-risk patients recruited and studied in the outpatient setting after 
hospitalization for HF; novel analytic techniques that utilized robust machine learning 
analyses with regularization; and validation of our findings in an independent HFpEF 
sample. Our study is also the first study to demonstrate the feasibility and utility of 
“phenomapping” for the unbiased categorization of a cardiovascular disorder. The 
prospective nature of our study, and the ascertainment of outcome data, allowed us to 
determine the clinical utility of the phenomapping technique in predicting differential risk of 
the study participants. Finally, although we enrolled a primarily urban population of patients 
who were previously hospitalized for HF, we enrolled a larger proportion of African 
Americans compared to other HFpEF studies, and the inclusion of patients previously 
hospitalized for HFpEF allowed us to study the highest risk patients and those most likely to 
be enrolled in clinical trials.
Although we were able to provide validation of the phenomapping technique via (1) 
demonstration of the prognostic utility of the pheno-grouping; and (2) successful validation 
of our findings in a separate, independent sample of HFpEF patients at Northwestern 
University, a potential limitation of our study is the lack of validation in a truly external 
cohort. Future studies that replicate our techniques in external HFpEF cohorts (i.e., in other 
institutions, hospitals, or multi-center studies) will be important to further demonstrate 
generalizability.
Conclusions
This is the first study to conduct high-density phenotypic classification (i.e., phenomapping) 
of a clinical cardiovascular syndrome. We have shown that unbiased cluster analysis of 
dense phenotypic data from multiple domains is feasible and can result in meaningful, 
clinically relevant categories of HFpEF patients, with significant differences in underlying 
etiology/pathophysiology and differential risk of adverse outcomes. Given the 
heterogeneous nature of HFpEF, phenomapping could be helpful for improved classification 
and categorization of HFpEF patients, and may lead to development of novel targeted 
therapies. Furthermore, phenomapping could help inform the design and conduct of future 
clinical trials and may be used to identify responders to therapies, thereby improving the 
unacceptably poor track record of HFpEF clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Phenotype Heatmap (PhenoMap) of HFpEF. Columns represent individual study 
participants and rows represent individual phenotypes. Red = increased value of a 
phenotype; Blue = decreased value of a phenotype.
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Bayesian Information Criterion Analysis for the Identification of the Optimal Number of 
Pheno-Groups.
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Outcomes by HFpEF Pheno-Group. Stacked bar graph of outcomes shows the step-wise 
increase in adverse events from pheno-group #1 to pheno-group #3.
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Survival Free of Cardiovascular Hospitalization or Death, Stratified by Pheno-Group. 
Kaplan-Meier curves for the combined outcome of heart failure hospitalization, 
cardiovascular hospitalization, or death, stratified by pheno-group. CV = cardiovascular.
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Table 1
Phenotype Domains and Individual Phenotypes
Phenotypic Domain Phenotypes
Demographics Age
Physical characteristics Body-mass index, heart rate, systolic blood pressure, diastolic blood pressure, pulse pressure
Laboratory Sodium, potassium, bicarbonate, blood urea nitrogen, creatinine, estimated GFR, fasting glucose, white 
blood cell count, hemoglobin, red cell distribution width, platelet count, B- type natriuretic peptide
Electrocardiography PR interval, QRS duration, QTc interval, QRS axis, T wave axis, QRS-T angle
Echocardiography
• Left heart structure LV end-diastolic volume, LV end-systolic volume, LV end-diastolic dimension, LV end-systolic dimension, 
septal wall thickness, posterior wall thickness, LV mass, left atrial volume
• LV systolic function LV ejection fraction, tissue Doppler s’ velocity (septal and lateral), velocity of circumferential fiber shortening
• LV diastolic function Mitral inflow characteristics (E velocity, A velocity, E/A ratio, E deceleration time, IVRT), tissue Doppler 
characteristics (septal e′ and lateral e′ velocities; septal a′ and lateral a′ velocities; septal E/e′ and lateral E/e′ 
ratios).
• Right heart structure RV basal diameter, RV maximal diameter, RV length, RV wall thickness, RV end-diastolic area, RV end-
systolic area, RV/LV maximal diameter ratio, right atrial area
• RV function RV fractional area change, tricuspid annular plane systolic excursion
• Hemodynamics Stroke volume, cardiac output, PA systolic pressure, RA pressure
• Pressure-volume analysis Effective arterial elastance, end-systolic elastance, systolic blood pressure/end-systolic volume ratio, end-
diastolic elastance, ventricular-arterial coupling, preload recruitable stroke work, pulse pressure/stroke 
volume ratio
Bolded phenotypes are those that were used in the model-based clustering analyses after filtering to remove correlated variables (R>0.6).
GFR = glomerular filtration rate; LV = left ventriular; RV = right ventricular; IVRT = isovolumic relaxation time; PA = pulmonary artery; RA = 
right atrial
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Table 2
Objective Criteria for Heart Failure with Preserved Ejection Fraction Diagnosis in the Entire Study Cohort
Parameter (Total N=397)
Prior hospitalization for symptomatic heart failure, n (%) 397(100)
New York Heart Association class III or IV, n(%) 190(48)
Left ventricular ejection fraction, % 61±7
Left ventricular end diastolic volume index, ml/m2 41±12
Grade 2 or 3 diastolic dysfunction, n(%) 297(75)
Left atrial volume index, ml/m2 34±14
E/e′ ratio 17±9
B-type natriuretic peptide, pg/ml* 234(86–530)
Invasive pulmonary capillary wedge pressure, mmHg (N=216) 23±9
Values expressed as mean±standard deviation unless otherwise specified
*
Median (25th–75th percentile)
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Table 3
Clinical and Laboratory Characteristics Stratified by Pheno-Group
Clinical characteristic Group 1 (N=128) Group 2 (N=120) Group 3 (N=149) P-value
Age, years 60.7±13.6 65.7±11.3 67.3±13.1 <0.001
Female, n(%) 86 (67) 81 (68) 82 (55) 0.049
Race, n(%) 0.32
 White 72(56) 58(48) 77(52)
 Black 42(33) 54(45) 56(37)
 Other 14(11) 8(7) 16(11)
NYHA functional class, n(%) 0.17
 I 25(20) 11(9) 13(9)
 II 61(48) 40(33) 56(38)
 III 38(30) 64(53) 78(52)
 IV 3(2) 5(4) 2(1)
Comorbidities, n(%)
 Coronary artery disease 54 (42) 58 (48) 75 (50) 0.38
 Hypertension 84 (66) 108 (90) 112 (75) <0.001
 Hyperlipidemia 65 (51) 75 (62) 73 (49) 0.06
 Diabetes mellitus 12 (9) 63 (52) 50 (34) <0.001
 Obesity 65 (51) 84 (70) 55 (37) <0.001
 Chronic kidney disease 8 (6) 41 (34) 79 (53) <0.001
 Atrial fibrillation 17 (13) 26 (22) 64 (43) <0.001
 Chronic obstructive pulmonary disease 43 (34) 46 (38) 56 (38) 0.70
 Obstructive sleep apnea 35 (27) 60 (50) 46 (31) <0.001
Vital signs and laboratory data
 Heart rate, bpm 77.2±14.5 74.7±14.9 71.6±12.6 0.004
 Systolic blood pressure, mmHg 122.4±16.6 129.2±19.0 123.0±22.7 0.011
 Diastolic blood pressure, mmHg 73.3±10.2 70.1±10.2 67.3±13.6 <0.001
 Pulse pressure, mmHg 49.1±12.4 59.2±16.9 55.7±19.6 <0.001
 Body mass index, kg/m2 31.2±7.3 37.0±10.7 28.9±7.4 <0.001
 Serum sodium, mEq/L 139.0±3.0 138.4±2.6 137.9±2.9 0.01
 Blood urea nitrogen, mg/dl 13.7±4.5 24.4±11.8 33.6±19.9 <0.001
 Serum creatinine, mg/dl 0.9±0.2 1.3±0.4 2.3±2.2 <0.001
 Estimated GFR, ml/min/1.73m2 79.5±21.2 53.8±17.6 43.9±27.3 <0.001
 Fasting glucose, mg/dl 98.4±15.6 153.2±85.2 111.5±29.2 <0.001
 Hemoglobin, g/dl 12.5±1.7 11.8±1.8 11.4±1.9 <0.001
 B-type natriuretic peptide, pg/ml 72(26–161) 188(83–300) 607(329–1138) <0.001
Medications, n(%)
 ACE-inhibitor or ARB 61 (48) 84 (70) 72 (48) <0.001
 β-blocker 67 (52) 89 (74) 112 (75) <0.001
 Calcium channel blocker 31 (24) 45 (38) 44 (30) 0.073
 Nitrate 5 (4) 19 (16) 33 (22) <0.001
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Clinical characteristic Group 1 (N=128) Group 2 (N=120) Group 3 (N=149) P-value
 Loop diuretic 40 (31) 82 (68) 109 (73) <0.001
 Thiazide diuretic 31 (24) 35 (29) 26 (17) 0.073
 Statin 48 (38) 72 (60) 73 (49) 0.002
 Aspirin 48 (38) 62 (52) 75 (50) 0.042
Heart failure duration, months 0.8 (0.4–4.3) 0.9 (0.4–16.3) 0.9 (0.4–11.7) 0.21
MAGGIC risk score 15.6±6.7 19.8±5.8 22.8±7.5 <0.001
Categorical variables are presented as counts and percentages, continuous variables are presented as mean±SD, and right skewed variables are 
presented as median (25th–75th percentile)
NYHA = New York Heart Association; GFR = glomerular filtration rate; ACE = angiotensin converting enzyme; ARB = angiotensin receptor 
blocker
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Table 4
Electrocardiographic, Echocardiographic, and Invasive Hemodynamic Characteristics Stratified Pheno-Group
Parameter Group 1 (N=128) Group 2 (N=120) Group 3 (N=149) P-value
Electrocardiography
PR interval, ms 166.6±29.6 174.2±29.8 183.3±53.5 0.007
QRS duration, ms 93.8±21.0 91.3±13.6 112.7±33.3 <0.001
QTc interval, ms 450.6±35.2 449.8±34.0 464.6±48.9 0.005
QRS axis, degrees 10.7±39.0 20.4±38.4 −4.2±60.7 <0.001
QRS-T angle, degrees 42.6±41.7 53.4±44.0 86.6±54.0 <0.001
Echocardiography
LV end-diastolic volume, ml 81.2±23.4 84.2±24.0 84.6±32.3 0.56
LV end-systolic volume, ml 31.6±12.1 33.1±12.1 35.4±19.2 0.12
Relative wall thickness 0.47±0.11 0.49±0.09 0.56±0.20 <0.001
LV mass index, g/m2 89.1±22.6 96.4±26.3 122.0±47.3 <0.001
Left atrial volume index, ml/m2 29.1±11.1 31.5±10.6 40.9±16.7 <0.001
LV ejection fraction, % 61.8±5.6 61.2±6.5 60.0±7.1 0.05
Stroke volume, ml 84.8±22.9 88.6±32.0 80.7±31.3 0.09
Cardiac output, L/min/m2 6.5±2.0 6.6±2.5 5.8±2.6 0.006
Pulmonary artery systolic pressure, mmHg 35.3±9.7 43.5±14.6 51.2±16.3 <0.001
Right atrial pressure, mmHg 6.0±2.7 6.9±3.5 9.8±4.7 <0.001
E velocity, cm/s 93.2±28.6 103.2±34.5 118.2±40.9 <0.001
A velocity, cm/s 82.8±22.5 93.1±26.3 81.6±38.7 0.01
E/A ratio 1.2±0.5 1.1±0.4 1.7±1.0 <0.001
Tissue Doppler e′ velocity, cm/s 9.3±3.2 7.5±2.1 7.9±3.4 <0.001
E/e′ ratio 11.2±3.7 15.2±6.4 18.6±10.6 <0.001
Diastolic dysfunction grade, n (%) <0.001
 Normal diastolic function 21 (16) 9 (8) 2 (1)
 Grade I (mild) diastolic dysfunction 15 (12) 16 (13) 12 (8)
 Grade II (moderate) diastolic dysfunction 60 (47) 56 (47) 43 (29)
 Grade III (severe) diastolic dysfunction 23 (18) 31 (26) 83 (56)
 Indeterminate diastolic function 9 (7) 8 (7) 9 (6)
RV basal diameter, cm 3.6±0.6 3.8±0.5 4.2±0.8 <0.001
RV end-diastolic area index, cm/m2 12.4±2.1 12.7±2.4 16.2±4.7 <0.001
RV end-systolic area index, cm/m2 6.7±1.5 7.2±1.5 9.9±3.4 <0.001
RV wall thickness, cm 0.46±0.03 0.50±0.07 0.56±0.11 <0.001
RV fractional area change 0.46±0.06 0.43±0.05 0.40±0.08 <0.001
TAPSE, cm 2.2±0.6 2.1±0.6 1.7±0.6 <0.001
Invasive hemodynamics (N=216)
Right atrial pressure, mmHg 10.5±4.6 15.3±6.5 14.6±6.8 <0.001













Shah et al. Page 23
Parameter Group 1 (N=128) Group 2 (N=120) Group 3 (N=149) P-value
Pulmonary artery systolic pressure, mmHg 42.4±12.0 55.9±15.4 56.7±19.7 <0.001
Pulmonary artery diastolic pressure, mmHg 21.7±6.3 28.2±7.7 26.5±9.1 <0.001
Mean pulmonary artery pressure, mmHg 28.8±7.7 35.9±9.9 36.6±11.7 <0.001
Pulmonary capillary wedge pressure, mmHg 19.9±6.3 24.6±8.3 23.7±9.7 0.002
Pulmonary vascular resistance, Wood units 1.2±2.5 2.8±4.6 2.3±3.7 0.043
Cardiac output, L/min 6.1±2.1 6.5±2.1 5.8±2.3 0.15
Continuous variables are presented as mean±SD; LV=left ventricular; RV=right ventricular; TAPSE = tricuspid annular plane systolic excursion
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Table 5
Association of Pheno-Groups with Adverse Outcomes on Cox Proportional Hazards Analysis
Group 1 (N=128) Group 2 (N=120) Group 3 (N=149) P-value
Outcome, n(%)
 CV hospitalization 22 (17) 41 (34) 71 (48) <0.001
 HF hospitalization 10 (8) 36 (30) 52 (35) <0.001
 Death 5 (4) 18 (15) 36 (24) <0.001
 Combined endpoint 23 (18) 54 (45) 84 (56) <0.001
Unadjusted, HR (95% CI)
 CV hospitalization 1.0 2.4 (1.4–4.1)*** 3.9 (2.4–6.3)*** —
 HF hospitalization 1.0 4.8 (2.4–9.6)*** 5.7 (2.9–11.3)*** —
 Death 1.0 4.0 (1.5–10.9)** 6.5 (2.5–16.6)*** —
 Combined endpoint 1.0 3.0 (1.9–5.0)*** 4.4 (2.8–7.0)*** —
Model 1, HR (95% CI)
 CV hospitalization 1.0 2.4 (1.4–4.2)*** 4.0 (2.3–6.8)*** —
 HF hospitalization 1.0 4.9 (2.3–10.1) 5.7 (2.7–11.8)** —
 Death 1.0 3.0 (1.1–8.4)* 4.0 (1.5–10.6)** —
 Combined endpoint 1.0 2.9 (1.7–4.8)*** 4.1 (2.5–6.8)*** —
Model 2, HR (95% CI)
 CV hospitalization 1.0 2.1 (1.2–3.6)** 2.9 (1.7–5.1)*** —
 HF hospitalization 1.0 4.1 (1.9–8.6)*** 4.2 (2.0–9.1)*** —
 Death 1.0 2.2 (0.8–6.0) 1.7 (0.6–4.9) —





Model 1 = Pheno-groups + BNP; Model 2 = Pheno-groups + BNP + MAGGIC risk score
The MAGGIC risk score includes the following variables: age, ejection fraction, creatinine, diabetes, chronic obstructive pulmonary disease, 
systolic blood pressure, body-mass index, heart rate, New York Heart Association class, ACE-inhibitor use, beta-blocker use, heart failure duration, 
and current smoker.
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